PCV (procarbazine, lomustine, vincristine)
Checked 2026-09-09
Anaplastic oligodendroglioma and IDH-mutant, 1p/19q-codeleted gliomas, with radiotherapy (RTOG 9402 gave PCV before, EORTC 26951 after)
Also called PCV.
One cycle
every 42 days × 6 · about 36 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Lomustine (CCNU) Oral nitrosourea chemotherapy | 110 mg/m² | Oral | D1 | |
Procarbazine Alkylating-like methylhydrazine derivative | 60 mg/m² once daily | Oral | D8-21 | |
Vincristine Vinca alkaloid (microtubule inhibitor) | 1.4 mg/m² (maximum 2 mg) | IV | D8, 29 |
Cycles
6 (EORTC 26951); 4 intensified cycles in RTOG 9402
42-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- In both RTOG 9402 and EORTC 26951 (van den Bent, JCO 2013, doi 10.1200/JCO.2012.43.2229) adding PCV to radiotherapy roughly doubled median survival in 1p/19q-codeleted tumours.
- Haematological toxicity and vincristine neuropathy are the limits; temozolomide is often substituted in practice although the evidence is for PCV.
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.